FDA's Overhaul Of GMP Oversight Will Include Numerous Targeted Guidances
This article was originally published in The Pink Sheet Daily
Executive Summary
The initiative to develop risk-based oversight of drug manufacturing will enter a new, less frenetic phase at its two-year anniversary in August. The project is a carryover from Deputy Commissioner Crawford's first term as acting head of FDA.
You may also be interested in...
FDA Good Manufacturing Practices Initiative Report Slated For October
GMP initiative report will include final guidance on process analytical technologies and aseptic processing, as well as draft guidance on the use of quality systems and computerized systems in clinical trials. The release will also contain "white paper" on prioritizing manufacturing sites for inspections.
FDA Good Manufacturing Practices Initiative Report Slated For October
GMP initiative report will include final guidance on process analytical technologies and aseptic processing, as well as draft guidance on the use of quality systems and computerized systems in clinical trials. The release will also contain "white paper" on prioritizing manufacturing sites for inspections.
FDA Clinical Practices Oversight Will Move To Risk-Based Approach
The agency will begin reviewing how it regulates clinical trial research within a year, FDA Good Clinical Practice Director Lepay says at DIA annual meeting. Inspections will move from a "rote" approach towards a risk-based method modeled on the GMP risk management initiative.